Search results
Results from the WOW.Com Content Network
2C-B (4-bromo-2,5-dimethoxyphenethylamine), also known as Nexus, is a synthetic psychedelic drug of the 2C family, mainly used as a recreational drug. [2] [1] [4] It was first synthesized by Alexander Shulgin in 1974 for use in psychotherapy.
25B-NBOMe (NBOMe-2C-B, Cimbi-36, Nova, BOM 2-CB) is a derivative of the phenethylamine psychedelic 2C-B, discovered in 2004 by Ralf Heim at the Free University of Berlin. It acts as a potent full agonist for the 5HT 2A receptor .
These effects are common for most psychedelics in the substituted phenethylamine class. There is a strong similarity between the subjective effects caused by βk-2C-B and 2C-B. However, βk-2C-B is often described to be more stimulating and less psychedelic. This, combined with its long duration, could increase the perceived severity of the ...
While found only in the peripheral nervous system, a report does indicate that CB 2 is expressed by a subpopulation of microglia in the human cerebellum. [20] CB 2 receptors appear to be responsible for immunomodulatory [ 19 ] and possibly other therapeutic effects of cannabinoid as seen in vitro and in animal models.
In theory, dihydro-difuran analogs of any of the 2Cx / DOx family of drugs could be made, and would be expected to show similar activity to the parent compounds, 2-CB, DOB, DOM, etc. In the same way that 2C-B-FLY is the dihydro-difuran analog of 2C-B , the 8-iodo equivalent, "2C-I-FLY," would be the dihydro-difuran analogue of 2C-I , and the 8 ...
The cannabinoid receptor 2 (CB2), is a G protein-coupled receptor from the cannabinoid receptor family that in humans is encoded by the CNR2 gene. [5] [6] It is closely related to the cannabinoid receptor 1 (CB1), which is largely responsible for the efficacy of endocannabinoid-mediated presynaptic-inhibition, the psychoactive properties of tetrahydrocannabinol (THC), the active agent in ...
CBD is a very low-affinity CB 1 ligand, that can nevertheless affect CB 1 receptor activity in vivo in an indirect manner, while THCV is a high-affinity CB 1 receptor ligand and potent antagonist in vitro and yet only occasionally produces effects in vivo resulting from CB 1 receptor antagonism.
There are two known subtypes of cannabinoid receptors, termed CB 1 and CB 2. [6] [7] The CB 1 receptor is expressed mainly in the brain (central nervous system or "CNS"), but also in the lungs, liver and kidneys. The CB 2 receptor is expressed mainly in the immune system, in hematopoietic cells, [8] and in parts of the brain. [9] The protein ...